{"title":"A comparative study of gellan gum and xanthan gum versus commercial vehicles as pharmaceutical thickening agents in oral suspensions","authors":"Pauline Claraz , Luc Fillaudeau , Chloé Jadoul , Thomas Storme , Coralie Guillemot , Mélanie White-Koning , Florent Puisset , Cécile Arellano","doi":"10.1016/j.ejpb.2024.114622","DOIUrl":null,"url":null,"abstract":"<div><div>Pharmaceutical oral suspensions are the main form used for patients with dysphagia. Compounding these forms is challenging because they are thermodynamically unstable but must remain physically stable. Ready-to-use vehicles such as Inorpha® or Orablend® exist but these are not optimal, and physical stability can be improved using a thickening or suspending agent. High-acyl gellan gum is a European food additive (E418), also used in pharmaceutical preparations, as a gelling agent, stabilizer or thickener but never as a suspending agent. This study aimed to investigate and characterize the properties of high-acyl gellan gum as a suspending agent and to compare it with ready-to-use vehicles and with another suspending agent, xanthan gum. Rheological behaviour, sedimentation and resuspension of vehicles were studied with and without irbesartan used as a model insoluble drug. Viscosity stability was studied for 90 days at room temperature and controlled temperature. We show that the high-acyl gellan gum vehicle offers the best viscosity and stability results for use in pharmaceutical suspensions because it exhibits stable homogeneity and viscosity in time, regardless of storage temperature, and is compatible with safe administration in dysphagic patients after 90 days. High-acyl gellan gum appears to be a good suspending agent for pharmaceutical suspensions.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"207 ","pages":"Article 114622"},"PeriodicalIF":4.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093964112400448X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Pharmaceutical oral suspensions are the main form used for patients with dysphagia. Compounding these forms is challenging because they are thermodynamically unstable but must remain physically stable. Ready-to-use vehicles such as Inorpha® or Orablend® exist but these are not optimal, and physical stability can be improved using a thickening or suspending agent. High-acyl gellan gum is a European food additive (E418), also used in pharmaceutical preparations, as a gelling agent, stabilizer or thickener but never as a suspending agent. This study aimed to investigate and characterize the properties of high-acyl gellan gum as a suspending agent and to compare it with ready-to-use vehicles and with another suspending agent, xanthan gum. Rheological behaviour, sedimentation and resuspension of vehicles were studied with and without irbesartan used as a model insoluble drug. Viscosity stability was studied for 90 days at room temperature and controlled temperature. We show that the high-acyl gellan gum vehicle offers the best viscosity and stability results for use in pharmaceutical suspensions because it exhibits stable homogeneity and viscosity in time, regardless of storage temperature, and is compatible with safe administration in dysphagic patients after 90 days. High-acyl gellan gum appears to be a good suspending agent for pharmaceutical suspensions.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.